Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 14/20 | 0.68 |
| ▸ | CTNNB1 | P35222 | 14/20 | 0.68 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030136 | 0.92 | BCL9 (0.72) | BCL9CTNNB1PPARAPDE4B | |
| SCHEMBL4030141 | 0.92 | BCL9 (0.72) | BCL9CTNNB1PPARAPDE4B | |
| SCHEMBL4027327 | 0.87 | BCL9 (0.86) | BCL9CTNNB1PPARA | |
| SCHEMBL4030427 | 0.87 | BCL9 (0.88) | BCL9CTNNB1PPARAPDE4B | |
| SCHEMBL4030421 | 0.87 | BCL9 (0.88) | BCL9CTNNB1PPARAPDE4B | |
| SCHEMBL4027999 | 0.86 | BCL9 (0.76) | BCL9CTNNB1PPARA | |
| SCHEMBL4035035 | 0.86 | BCL9 (0.72) | BCL9CTNNB1PPARA | |
| SCHEMBL4031114 | 0.82 | PPARA (0.80) | BCL9CTNNB1PPARA | |
| SCHEMBL21425202 | 0.82 | BCL9 (0.56) | BCL9CTNNB1PPARAPRMT5USP30 | |
| SCHEMBL4033161 | 0.81 | BCL9 (0.69) | BCL9CTNNB1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567493-B1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PROD INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | BCL9 2684/4885CTNNB1 2280/4885PPARA 1/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | BCL9 2684/4885CTNNB1 2280/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.